GENE ONLINE|News &
Opinion
Blog

2025-11-29|

Scoping Review Explores Role of Explainable AI in Enhancing Athlete Performance and Injury Prevention

by GOAI
Share To

A recent scoping review by researchers S. Kranzinger, C. Halmich, and D. Hofer examines the role of explainable artificial intelligence (AI) in sports science, highlighting its potential to impact the field significantly. The study explores how AI technologies can be utilized to enhance athletic performance and optimize training methodologies while emphasizing the importance of transparency and interpretability in AI systems used within this domain.

The review focuses on the integration of explainable AI into sports science applications, addressing its ability to provide insights into complex data patterns related to athlete performance, injury prevention, and recovery processes. By prioritizing explainability, these AI systems aim to ensure that coaches, athletes, and medical professionals can understand and trust the recommendations generated by such technologies. The findings underscore a growing interest in leveraging advanced computational tools while maintaining clarity in their decision-making processes for practical implementation in sports science practices.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 29, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top